IPF PPF SSc-ILD Mechanism of Action Prescribing information Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline How to recognize ILD and PPF in patients with CTD 19/06/2024 | Author: Boehringer Ingelheim Document ID: PC-SA-102490 | Expiry Date: 29/05/2026 Ofev PPF Identify Patients With RA-ILD Who Can Benefit From OFEV SSc-ILD AE Management Animation - Management of diarrhea SSc-ILD AE Management Animation - Management of nausea and vomiting How to understand and manage limited cutaneous SSc-ILD Safety Profile of OFEV Treatment of patients with PPF and CTD-ILD How to recognize ILD and PPF in patients with CTD Related content Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102492 (May 2026 ) Watch now Opens in new tab Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102498 (May 2026 ) Download Opens in new tab Read more PDF Identify Patients With RA-ILD Who Can Benefit From OFEV PC-SA-101935 (August 2026 ) Download Opens in new tab Home Respiratory | Therapeutic Area Ofev Efficacy How to recognize ILD and PPF in patients with CTD
Read more 3:43 Treatment of patients with PPF and CTD-ILD PC-SA-102492 (May 2026 ) Watch now Opens in new tab
Read more PDF How to understand and manage limited cutaneous SSc-ILD PC-SA-102498 (May 2026 ) Download Opens in new tab
Read more PDF Identify Patients With RA-ILD Who Can Benefit From OFEV PC-SA-101935 (August 2026 ) Download Opens in new tab
